Premium
Intrahepatic activation of caspases in human fulminant hepatic failure
Author(s) -
Leifeld Ludger,
Nattermann Jacob,
Fielenbach Magdalene,
Schmitz Volker,
Sauerbruch Tilman,
Spengler Ulrich
Publication year - 2006
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2006.01300.x
Subject(s) - tunel assay , fulminant hepatic failure , fulminant , caspase , apoptosis , fulminant hepatitis , pathogenesis , hepatitis , medicine , immunology , pathology , biology , programmed cell death , biochemistry , liver transplantation , transplantation
Background/Aims: Apoptosis has been implicated in the pathogenesis of fulminant hepatic failure (FHF) potentially involving caspases. Thus far, apoptosis in FHF has mainly been studied in animal models while human data are sparse. Methods: Caspases‐3, ‐8 and ‐9 activities and Fas expression were analyzed in correlation to TdT‐mediated dUTP nick end labelling (TUNEL) positive apoptotic cells in livers of patients with FHF ( n =26), chronic liver disease (CLD) ( n =60) and normal controls (NC) ( n =10). Results: Numbers of TUNEL‐positive cells were higher in FHF than in CLD and NC ( P <0.001) correlating to the intrahepatic activities of caspase‐3. The highest caspase‐3 activities were found in fulminant hepatitis B, significantly surpassing those in FHF of any other etiology. In fulminant hepatitis B, caspase‐9 activity was also higher than in controls, while caspase‐8 activation was not higher than in NC. Unlike caspase‐3, caspases ‐8 and ‐9 activities were not correlated to the numbers of TUNEL positive cells. Fas expression was also the highest in FHF but did not differ between hepatitis B virus‐FHF and other FHF. Conclusions: Our data indicate differential activation of intrahepatic caspases in FHF depending on the underlying etiology. Massive activation of caspases in fulminant hepatitis B confirms a pivotal role of apoptotic pathways in the pathogenesis of human fulminant hepatitis B.